Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting now

Conditions studied: Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis

In brief

The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.

Key facts

Study ID

NCT06516406

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

1055

Starts

2022-05-06

Expected to finish

2032-05-31

Last updated by the study team

2024-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Patients diagnosed with Primary Myelofibrosis or secondary to Essential Thrombocythemia/Polycythemia vera who are being treated or have been treated with ruxolitinib therapy in accordance with normal clinical practice.
• Availability of data on clinical history prior to initiation of Ruxolitinib therapy
• Obtaining informed consent for data collection and processing

You may not qualify if…

• None

Where it is running

• Azienda Ospedaliera Annunziata — Cosenza, Calabria, Italy (enrolling)
• Grande Ospedale Metropolitano "Bianchi Melacrino Morelli" — Reggio Calabria, Calabria, Italy (enrolling)
• Università degli Studi di Napoli Federico II U.O.C. di Ematologia e Trapianti di midollo — Naples, Campania, Italy (enrolling)
• IRCCS Policlinico Sant'Orsola — Bologna, Emilia-Romagna, Italy (enrolling)
• Università degli studi di Ferrara - Nuovo Polo Ospedaliero di Cona - A.O.U. Arcispedale S. Anna — Ferrara, Emilia-Romagna, Italy (enrolling)
• Azienda Ospedaliero-Universitaria di Parma — Parma, Emilia-Romagna, Italy (enrolling)
• AUSL di Piacenza - Palazzine Medicine Specialistiche — Piacenza, Emilia-Romagna, Italy (enrolling)
• Dipartimento Oncoematologico - AUSL della Romagna — Ravenna, Emilia-Romagna, Italy (enrolling)
• Ospedale Infermi di Rimini — Rimini, Emilia-Romagna, Italy (enrolling)
• A.O.U. Integrata di Udine — Udine, Friuli Venezia Giulia, Italy (enrolling)
• A.O.U. Policlinico Umberto I - Università degli Studi di Roma "La Sapienza" — Rome, Lazio, Italy (enrolling)
• Ospedale S. Eugenio — Rome, Lazio, Italy (enrolling)
• Ospedale Belcolle — Viterbo, Lazio, Italy (enrolling)
• IRCCS Azienda Ospedaliera Universitaria "San Martino" - IST — Genoa, Liguria, Italy (enrolling)
• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Lombardy, Italy (enrolling)
• Ospedale San Gerardo — Monza, Lombardy, Italy (enrolling)
• Ospedale San Luigi Gonzaga - Regione Gonzole — Turin, Piedmont, Italy (enrolling)
• Department of Oncology, University of Torino — Turin, Piedmont, Italy (enrolling)
• Città della Salute e della Scienza — Turin, Piedmont, Italy (enrolling)
• A. O. Ordine Mauriziano di Torino — Turin, Piedmont, Italy (enrolling)
• Ospedale "A. Businco" - Dipartimento Scienze Mediche e Sanità Pubblica Università degli Studi di Cagliari — Cagliari, Sardinia, Italy (enrolling)
• A.O.U. "Policlinico-V. Emanuele"- P.O. Ferrarotto — Catania, Sicily, Italy (enrolling)
• A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore — Pesaro, The Marches, Italy (enrolling)
• Policlinico S.Maria alle Scotte — Siena, Tuscany, Italy (enrolling)
• AOU di Padova — Padova, Veneto, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.